A. D. Beadell Investment Counsel Inc. Sells 198 Shares of Illumina, Inc. (NASDAQ:ILMN)

A. D. Beadell Investment Counsel Inc. lessened its holdings in Illumina, Inc. (NASDAQ:ILMN) by 7.5% during the fourth quarter, HoldingsChannel.com reports. The firm owned 2,457 shares of the life sciences company’s stock after selling 198 shares during the period. A. D. Beadell Investment Counsel Inc.’s holdings in Illumina were worth $328,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Geode Capital Management LLC grew its stake in shares of Illumina by 1.8% in the third quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock valued at $354,933,000 after buying an additional 48,018 shares in the last quarter. Primecap Management Co. CA increased its stake in shares of Illumina by 3.6% during the 3rd quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock worth $328,158,000 after purchasing an additional 87,599 shares during the last quarter. Janus Henderson Group PLC raised its holdings in shares of Illumina by 40.5% in the 3rd quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after purchasing an additional 625,245 shares during the period. Millennium Management LLC lifted its stake in Illumina by 305.0% in the 2nd quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock valued at $155,067,000 after purchasing an additional 1,118,747 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Illumina by 4.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,260,137 shares of the life sciences company’s stock worth $164,334,000 after purchasing an additional 54,319 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analysts Set New Price Targets

ILMN has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. raised their price objective on Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Canaccord Genuity Group raised their price target on Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a report on Tuesday, November 5th. Morgan Stanley reiterated an “equal weight” rating and issued a $156.00 price objective on shares of Illumina in a report on Tuesday, November 12th. Piper Sandler cut their target price on shares of Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. Finally, Royal Bank of Canada upped their price target on shares of Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. Eight investment analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $165.95.

Illumina Price Performance

ILMN stock traded down $5.02 during mid-day trading on Friday, hitting $134.66. The stock had a trading volume of 470,069 shares, compared to its average volume of 1,245,201. The firm has a fifty day simple moving average of $141.37 and a 200 day simple moving average of $132.08. The firm has a market capitalization of $21.36 billion, a P/E ratio of -13.52 and a beta of 1.11. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a 52 week low of $100.08 and a 52 week high of $156.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. During the same period last year, the firm posted $0.33 earnings per share. The firm’s quarterly revenue was down 3.5% compared to the same quarter last year. As a group, research analysts forecast that Illumina, Inc. will post 4.11 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.